Dyspareunia Clinical Trial
Official title:
A Comparison of Cognitive-behavioral Couple Therapy and Lidocaine in the Treatment of Provoked Vestibulodynia: A Randomized Clinical Trial
Chronic pain problems involving the female reproductive system are major health concerns for all women. Poorly understood, they entail great personal and financial cost. One such condition is vulvodynia, or chronic unexplained vulvar pain, which has a prevalence of 16%. Despite its negative impact on psychosexual and relationship satisfaction, there is little research examining empirically-tested treatments for afflicted couples. The proposed research builds on findings from our work focusing on the impact of relational factors on vulvodynia, and our previous research evaluating the efficacy of group cognitive-behavioral therapy for this problem. This two-centre randomized clinical trial aims to assess the efficacy of a novel, 12-week targeted couple therapy (CBCT) for women with vulvodynia in comparison to one of the most commonly prescribed first line medical interventions, topical lidocaine. Primary research question: Is there a significant difference between the two treatments on women's pain during intercourse post-treatment? Secondary research questions will assess for significant differences between the two treatments post-treatment and at 6-month follow-up on multidimensional aspects of pain using the McGill Pain Questionnaire, women and partners' sexuality (sexual function and satisfaction), psychological adjustment (anxiety, depression, catastrophizing, self-efficacy, attributions, and quality of life), relationship factors (partner responses, couple satisfaction, attachment, and communication styles), and self-reported improvement and treatment satisfaction. Results of this study will improve the health and quality of life of patients with vulvodynia by rigorously testing the efficacy of a novel couples treatment.
Background: Chronic pain problems involving the female reproductive system are major health
concerns in women of all ages. As conditions which are poorly understood and often
misdiagnosed or ignored, they entail a great personal cost to patients and a significant
financial cost to society. One such condition is vulvodynia, or chronic unexplained vulvar
pain. A recent population-based study suggests that the lifetime cumulative incidence of
vulvodynia is 16%, indicating that approximately 2.5 million Canadian women may experience
idiopathic vulvar pain during their lifetimes. Provoked vestibulodynia (PVD) - an acute
recurrent pain localized within the vulvar vestibule and experienced primarily during sexual
intercourse - is suspected to be the most frequent cause of vulvodynia in premenopausal
women, with prevalence estimates of 12% in community samples. Despite its high prevalence and
negative impact on psychosexual functioning, there has been a paucity of controlled research
to provide empirically validated treatments for afflicted couples. The present proposal draws
on our previous cross-sectional and prospective CIHR funded research on the dyadic
determinants of pain and psychosexual impairment in women with PVD and their partners, as
well as on our past randomized trials evaluating the efficacy of group cognitive-behavioral
therapy for this condition. Specifically, the goal of our study is to evaluate the efficacy
of a targeted cognitive-behavioral couple therapy (CBCT) intervention that we developed for
the treatment of PVD.
Objectives: The proposed two-centre randomized clinical trial aims to evaluate the efficacy
of a novel 12-week targeted couple therapy intervention (CBCT) for women with PVD in
comparison to one of the most frequently prescribed first line medical interventions, topical
lidocaine, shown to be effective and safe in the management of PVD. The primary research
question focuses on whether there is a significant difference between the two treatments on
women's pain during intercourse post-treatment. Secondary research questions focus on whether
there are significant differences between the two treatments post-treatment and at 6-month
follow-up on (a) the multidimensional aspects of women's pain on the McGill Pain
Questionnaire and (b) women and partners' sexuality (sexual function and satisfaction,
frequency of intercourse), psychological adjustment (anxiety, depression, catastrophizing,
self-efficacy, pain attributions, quality of life, acceptance of pain, compassionate love for
partner, self-compassion, emotion regulation and thoughts and feelings related to pain
experience), relationship factors (partner responses, dyadic adjustment, attachment, and
communication) and self-reported improvement and treatment satisfaction. We will also examine
whether childhood trauma and co-morbid pain conditions moderate treatment response. Finally,
a third research question is to evaluate the role of hormonal contraceptive use and the risk
of PVD.
Research plan/methodology: The proposed research is a 3.5-year, two-centre parallel
randomized controlled trial for PVD using an intent-to-treat analysis strategy, with pain
during intercourse as the primary outcome. The main research questions will be addressed by:
1) recruiting 224 premenopausal women and their partners with medically diagnosed PVD; 2)
performing comprehensive gynecological and psychosexual pre-treatment evaluations focusing on
our outcome measures; 3) randomly assigning women to one of the two 12-week treatment arms:
CBCT or lidocaine, and 4) evaluating pain during intercourse, as well as sexual,
psychological and relationship outcomes, in addition to self-reported improvement and
treatment satisfaction, post-treatment and at 6-month follow-up. These procedures will take
place in two different university centers: Université de Montréal in Montréal, Québec, and
Dalhousie University in Halifax, Nova Scotia, and their affiliated hospitals. Both university
centres will store data securely, adhering to the protocols outlined by the ethics review
boards at each site.
Statistical Analyses: Analyses will be conducted based on intention to treat. Descriptive
statistics will be used to define and compare the participants in both intervention groups.
More specifically, we will calculate means, medians, deviations and interquartile ranges and
T-tests will be used to determine the differences between groups for socio-demographic
variables. Chi-square tests and observed differences between groups will be used for
categorical variables. If differences are observed between groups, these variables will be
controlled for in subsequent analyses. We will verify that variables are normally
distributed. If variables are not normally distributed, non-parametric tests will be
employed. A repeated measures analysis of variance will permit the assessment of efficacy of
the two treatments at post-treatment and at 6-month follow-up. The analyses will focus on the
changes in pain experienced during intercourse from pre-treatment assessment to
post-treatment and 6-months follow-up. To do this, time will be the intra-subject variable,
and the experimental condition will be the inter-subject variable.
For secondary analysis, multiple analyses will be conducted in multiple steps, with
multivariate analyses being conducted first for repeated measures (MANOVA). Correlated
measures will be grouped based on conceptual domain (e.g., pain, dyadic adjustment,
catastrophizing). Univariate analyses will be conducted if the multivariate results are
significant (ANOVA). This will be followed by orthogonal contrasts to examine changes between
different measurements. Moreover, we will use exploratory analyses for participants who
completed the experimental protocol to determine the effect protocol adherence has on
treatment efficacy. Multiple regression analyses will be used to examine the link between
socio-demographic variables, pre-treatment dependent variables and pain at post-treatment and
6-months follow-up to identify factors associated with therapeutic success. These latter
analyses will be conducted for each treatment group separately. Bonferroni corrections will
be used during analyses for multiple comparison adjustments. In the case of missing data, we
will explore the effects of withdrawal on sensitivity analyses, replace the missing data with
data from the most recent assessment or with averaged or aggregate values.
Significance of study: Results of the proposed research may improve the health and quality of
life of Canadians afflicted with a highly prevalent and neglected women's health problem -
vulvodynia - by providing a rigorous test of the efficacy of a novel targeted couple therapy
intervention.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03935698 -
Physiotherapy Treatment in Women With Dyspareunia Following Gynecological Cancer: a Pilot Study
|
N/A | |
Recruiting |
NCT03427255 -
CBT Group Treatment for Women With Dyspareunia
|
N/A | |
Completed |
NCT02253173 -
Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT03184077 -
Rapidly Absorbing Polyglactin 910 Versus Poliglecaprone 25 for Laceration Repair
|
N/A | |
Recruiting |
NCT05445115 -
The Mollie Study, a Study to Evaluate the Safety and Efficacy of the Mollie Medical Device
|
N/A | |
Withdrawn |
NCT03666819 -
Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy
|
Phase 2 | |
Active, not recruiting |
NCT03681678 -
Laser Therapy for Treatment of Urogenital Symptoms in Women
|
||
Completed |
NCT04955418 -
Effects of Epi-no Device on Pelvic Floor Dysfunctions
|
N/A | |
Completed |
NCT05834088 -
Effects of Myofascial Release With and Without Thiele Massage
|
N/A | |
Terminated |
NCT03185169 -
GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors
|
Early Phase 1 | |
Completed |
NCT03307044 -
Fractional CO2 Laser Therapy for Survivors of Breast Malignancies
|
N/A | |
Completed |
NCT05617820 -
Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy
|
Phase 3 | |
Recruiting |
NCT03714581 -
Laser Therapy Following Radiotherapy for Gynecological Cancer
|
N/A | |
Completed |
NCT04659668 -
Evaluation of the Efficacy and Safety of the Dermal Filler for Female Intimate Area Hydration and Atrophy of the Vagina.
|
N/A | |
Completed |
NCT03199534 -
A Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction
|
Phase 4 | |
Completed |
NCT00318500 -
Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women
|
Phase 2 | |
Recruiting |
NCT05540353 -
Transvaginal Low-level Laser Therapy to Improve Pelvic Pain and Sexual Function in Patients With Endometriosis.
|
N/A | |
Completed |
NCT03178825 -
Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause
|
N/A | |
Completed |
NCT04389489 -
Postpartum Sexual Function in Pregnant Women With COVID-19
|
||
Completed |
NCT03372720 -
Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors
|
N/A |